Histopathogenesis of Malignant Skin Melanoma Induced in Genetically

Total Page:16

File Type:pdf, Size:1020Kb

Histopathogenesis of Malignant Skin Melanoma Induced in Genetically Proc. Natl. Acad. Sci. USA Vol. 90, pp. 8822-8826, October 1993 Medical Sciences Histopathogenesis of malignant skin melanoma induced in genetically susceptible transgenic mice (melanocytdc hyperplasa/nevi/ulceratdon/invaslon/metastss) BEATRICE MINTZ*, WILLYS K. SILVERS, AND ANDRES J. P. KLEIN-SZANTO Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA 19111 Contributed by Beatrice Mintz, June 28, 1993 ABSTRACT Animal models ofhuman malignant skin mel- Unexpectedly, melanocytes in the grafted skin proliferated anoma were created in melanoma-susceptible Inbred-strain excessively and selectively, close to areas of greatest wound transgenic mice by grafting skin from donors of high- healing, especially near the graft margins (3), thereby strongly susceptibiliblines to hosts of a low-susceptibility line, thereby suggesting a causal role of growth factors and cytokines overcoming the problem ofearly death ofthe more susceptible associated with wound repair (4). The melanocytic lesions animals from eye melanomas. As already descbed [Mintz, B. progressed to malignant melanoma in all skin grafts from the & Silvers, W. K. (1993) Proc. Nadl. Acad. Sci. USA 90, more susceptible of two transgenic donor lines tested, and in 8817-8821], melanocs within the grad selectively prolifer- one-fourth of the grafts from another line; no melanomas of ated in close proimity to areas of greatest wound healing, host onrgin developed. We have proposed that the induction of presumably in reponse to mitogenic factors fom ceils con- this maliancy in susceptible skinby wound healing is merely tributing to wound repair. An orderly sequence of externally a caricature or exaggeration of the same basic biological and visible events ed in malinant melanoma. We emne molecular events as ordinarily underlie the genesis of mela- here the hisogenetic concomitants of these changes and find noma, without skin grafting, and that the exaggeration makes that they deflne a sepwie sequence striknly comparable to those events more accessible to analysis (3). that leding to human cutaneous melanoma. Moreover, the From the externally visible evidence ofprogressive changes histological detais suggest some ofthe underlying mechanisms. in the lesions, we concluded that the development of the While the early lesions are first seen in the superficial dermis transgenic melanomas bears a stiking resemblance to that of in the mouse, and in the basal layer of the epidermis in the human skin melanomas and is an excellent in vivo model ofthe human, both progress by radial growth followed by vertical human malignancy (3). This model has the further advantages growth. Melanocytic hyperplasa resulted in nests of densely ofgenetic uniformity and ofthe absence ofany other kinds of melanied fisform cells which were lodng their dendrites. skin tumors in the animals. In the present report, we describe Some discrete lesons in the deep dermis appered as blue nevi. the histogenetic evidence in support of a multistep tumor As radial proferation advanced, ceilular atypia insed and progression paralleling the sequence in human cutaneous the preiouly independent melanocytes cohered dosely and melanomas. In addition, details visible only at the microscopic formed a smail solid tumor; the ceils were usua_ly then hy- level suggest mechanisms on which some of the changes pomelanotic or amelanotic. Ulceration of tumor through the leading to malignancy may depend. epidermis ourrd early. The tumor mass grew rapidly in the deep dermis and invaded and destroyed subcutaneous tissue MATERIALS AND METHODS and muscle. Primary tumors in the skin were often heteroge- neous, with lobules or regions differing in pigmentation or The same transgenic mouse lesions as in the companion atypia. However, the cells in crulating emboli, or in metas- report (3) were examined histologically here. These orgi- tases in lymph nodes and lungs, appeared relatively homoge- nated in donor body-skin grafts from line 8 [hemizygous for neous. These genetically uniform transgenic mouse models the transgene (Tag!-), and line 9 (Tag/Tag homozygotes), provide experimental access to the multistage genesis of mel- each developing in a line 12 (Tag!-) host. Wild-type body- anoma. skin grafts, experimentally wounded but ungrafted transgenic skin, and unmanipulated wild-type and transgenic skin were The Tyr-SV40E transgene targets expression of the simian also included. Tissues were fixed in neutral formalin, em- virus 40 oncogenic sequences to pigment cells in transgenic bedded in paraffin, and stained with hematoxylin/eosin. mice and results in spontaneous malignant melanomas of the Some sections were immunostained as described (1) to vi- eyes and various internal organs; skin melanomas tend to sualize the S-100 or HMB-45 proteins associated with ma- arise later (1, 2) and have only rarely attained malignancy lignant melanoma. Staining for 3,4-dihydroxyphenylalanine before the mice die-usually of invasive and metastatic eye (dopa) was used in some cases to detect nonmelanized melanomas. This problem was recently overcome, and ma- pigment cells (along with melanized ones). lignant skin melanomas were obtained, by taking advantage experimentally of the fact that different inbred lines of the RESULTS AND DISCUSSION mice differ in level of expression of the transgene and hence in degree of susceptibility to melanoma; yet all are members Melanocytes in C57BL/6 Wild-Type and Transgenic Body ofthe same standard strain, C57BL/6. Thus, by grafting skin Skin. Pigmented melanocytes in the fur-bearing body skin of from high-susceptibility transgenic donors to low-suscepti- the wild-type C57BL/6 mouse occur chiefly within the hair bility transgenic hosts, the skin outlived the donors in im- follicles. They are virtually absent in the body skin outside munocompetent hosts tolerant of the transgene product (3). the follicles, although they are present in the skin of other regions such as the ears and tail (5). Some dopa-positive The publication costs ofthis article were defrayed in part by page charge unpigmented melanocytes (or melanoblasts) persist in the payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. *To whom reprint requests should be addressed. 8822 Downloaded by guest on September 27, 2021 Medical Sciences: Mintz et al. Proc. Natl. Acad. Sci. USA 90 (1993) 8823 epidermis and superficial dermis ofbody skin and synthesize most densely pigmented areas ofthe grafts, discrete blue nevi melanin when the mice are exposed to ultraviolet light (6). In were not apparent externally; however, similar lesions were contrast, pigmented melanocytes occur in the epidermis and found histologically. Among the several dozen melanocytes dermis ofhuman body skin, especially in the basal layer ofthe in such nevi, some were spindle shaped and others were epidermis (7). The epidermis itself is much thinner in the epithelioid (Fig. 1 c and d). The admixture with dense dermal haired areas of mouse skin than in human skin and has collagen fibers, other connective tissue elements, and mela- less-defined strata. nin-containing macrophages (or melanophages) was similar The body skin of Tyr-SV40E transgenic control mice was to the description of human blue nevi (13). found to differ from wild-type controls of the same inbred Melanomas. In no case did a discrete and isolated blue strain in having occasional pigmented melanocytes in the nevus, situated outside the regions of wound-associated superficial dermis and mid-dermis. In older transgenics, the dense melanocytic hyperplasia, become a melanoma in the cells were seen in the mid-dermis and deep dermis. Small flat course of the graft experiment, spanning over 1 year. It is black spots or macules also appeared spontaneously in the therefore likely that many of these are indolent lesions older transgenic mice. The macules had regular borders and generally destined to remain benign, as is often the case in the consisted of groups of loosely associated pigment cells in the human cellular blue nevus (13). Nevertheless, the very grad- dermis. The accumulation of pigmented cells in unusual num- ual nature ofthe series ofchanges seen in our skin grafts, and bers or sites has also been described in various internal organs the physical contiguity of nevi, blue nevi, atypical nevi (14), of the transgenic mice and was referred to as melanosis (2). and melanoma, support the view that certain nevi are in fact Melacytic Hyperp_sa In Grafted Transgec Skin. After the precursors ofthe mouse melanomas, as is likely in human transplantation, the number of isolated melanocytes in the melanomas (15). In Fig. ld, this contiguity is apparent in the dermis increased, in comparison with ungrafted transgenic deep dermal blue nevus (right arrowhead), the transitional skin of similar age, so that scattered dendritic pigment cells area (immediately above) with decreasing cellular melaniza- were not difficult to find (Fig. la). A much more striking tion, and the early melanoma (left arrowhead). It seems change appeared within a few weeks after grfting and was possible that paracrine influences are needed for nevi to make readily apparent externally as a blackened localized ringjust this transition; such factors may be more readily available inside the margins of the graft and occasionally as a more where injury and wound repair are in progress. irregular black tracery in the interior of the graft (3). These As documented in Fig. 1 c, d, and g, atypical
Recommended publications
  • Beatrice Mintz Date of Birth 24 January 1921 Place New York, NY (USA) Nomination 9 June 1986 Field Genetics Title Jack Schultz Chair in Basic Science
    Beatrice Mintz Date of Birth 24 January 1921 Place New York, NY (USA) Nomination 9 June 1986 Field Genetics Title Jack Schultz Chair in Basic Science Professional address The Institute for Cancer Research Fox Chase Cancer Center 7701 Burholme Avenue, Room 215 Philadelphia, PA 19111 (USA) Most important awards, prizes and academies Awards: Bertner Foundation Award in Fundamental Cancer Research (1977); New York Academy of Sciences Award in Biological and Medical Sciences (1979); Papanicolaou Award for Scientific Achievement (1979); Lewis S. Rosenstiel Award in Basic Medical Research (1980); Genetics Society of America Medal (1981); Ernst Jung Gold Medal for Medicine (1990); John Scott Award for Scientific Achievement (1994); March of Dimes Prize in Developmental Biology (1996); American Cancer Society National Medal of Honor for Basic Research (1997); Pearl Meister Greengard Prize (2008); Albert Szent-Györgyi Prize for Progress in Cancer Research (2011). Academies: National Academy of Sciences (1973); Fellow, American Association for the Advancement of Science (1976); Honorary Fellow, American Gynecological and Obstetrical Society (1980); American Philosophical Society (1982); Fellow, American Academy of Arts and Sciences (1982); Pontifical Academy of Sciences (1986). Degrees: Doctor of Science, New York Medical College (1980); Medical College of Pennsylvania (1980); Northwestern University (1982); Hunter College (1986); Doctor of Humane Letters, Holy Family College (1988). Summary of scientific research Beatrice Mintz discovered the underlying relationship between development and cancer. She first showed that development is based on an orderly hierarchical succession of increasingly specialized small groups of precursor or "stem" cells, expanding clonally. She proposed that cancer involves a regulatory aberration in this process, especially in the balance between proliferation and differentiation.
    [Show full text]
  • Changes in Expression of Putative Antigens Encoded by Pigment
    Proc. Natl. Acad. Sci. USA Vol. 92, pp. 10152-10156, October 1995 Medical Sciences Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression (albino locus/brown locus/slaty locus/silver locus) SETH J. ORLOW*, VINCENT J. HEARINGt, CHIE SAKAIt, KAZUNORI URABEt, BAO-KANG ZHOU*, WILLYS K. SILVERSt, AND BEATRICE MINTZO§ *Ronald 0. Perelman Department of Dermatology and Department of Cell Biology, New York University School of Medicine, New York, NY 10016; tLaboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; and tInstitute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA 19111 Contributed by Beatrice Mintz, July 25, 1995 ABSTRACT Cutaneous melanomas of Tyr-SV40E trans- This problem might be overcome by identifying changes in genic mice (mice whose transgene consists of the tyrosinase the antigenic profile associated with melanoma progression promotor fused to the coding regions of simian virus 40 early such that the design of a treatment protocol could encompass genes) strikingly resemble human melanomas in their devel- all the melanoma cells. Such a characterization in the case of opment and progression. Unlike human melanomas, the human melanoma would be complicated by genetic differences mouse tumors all arise in genetically identical individuals, among individuals, especially as the genetic background, as thereby better enabling expression of specific genes to be well as allelic differences at pigment gene loci themselves, can characterized in relation to advancing malignancy. The prod- influence the expression and interactions of these genes (11, ucts of pigment genes are of particular interest because 12).
    [Show full text]
  • From Blastomeres to Somatic Cells: Reflections on Cell Developmental Potential in Light of Chimaera Studies – a Review
    Animal Science Papers and Reports vol. 35 (2017) no. 3, 225-240 Institute of Genetics and Animal Breeding, Jastrzębiec, Poland From blastomeres to somatic cells: reflections on cell developmental potential in light of chimaera studies – a review Krystyna Żyżyńska-Galeńska*, Anna Piliszek, Jacek A. Modliński Department of Experimental Embryology, Institute of Genetics and Animal Breeding, Polish Academy of Sciences, Jastrzębiec, 05-551 Magdalenka, Poland (Accepted June 10, 2017) Mammalian development is a process, whereby cells from a totipotent zygote gradually lose their potency, i.e. their ability to differentiate, in the environment of the developing embryo. An ideal model for testing the real potential of cells is the experimental production of chimaeras. The first experimentally produced mammalian (murine) chimaeras were created by Tarkowski [1961] and since then many new methods of chimaera production have been developed, including injecting cells into the blastocyst’s cavity or into cleaving embryos. This review describes how different cell types, depending on the developmental stage or culture conditions, manifest their potential to contribute to chimaeras. Cell developmental potential has been analysed in pluripotent blastomeres, which can contribute to all embryonic and extra-embryonic lineages, albeit differently depending on their developmental stage. This is the case in blastocyst lineages, with various developmental potentials depending on the surrounding cells, and in more differentiated cells from different stages of pregnancy, which in some cases may colonise chimaeric animal tissue. Cell potential has also been analysed in embryonic stem and embryonal carcinoma cells, which are pluripotent and efficiently contribute to chimaeras; in multipotent fetal and adult stem cells, which can also participate in chimaera formation; and in somatic mouse embryonic fibroblasts (MEFs), which can also be reprogrammed in the environment of the cleaving embryo.
    [Show full text]
  • Blanche Capel, Phd FASEB Board of Directors
    Blanche Capel, PhD FASEB Board of Directors Blanche Capel, PhD, is a James B. Duke Professor of Cell Biology at Duke University Medical Center, where she began her research laboratory in 1993. Her graduate training was in mouse genetics and stem cell biology with Beatrice Mintz at Fox Chase Cancer Center and the University of Pennsylvania, followed by postdoctoral research in the Lovell-Badge laboratory at the National Institute for Medical Research, Mill Hill, London, leading to the discovery of Sry, the male sex determining gene in mammals. Work from the Capel laboratory is prominent in the field of primary sex determination and the cell fate and patterning decisions that underlie the development of the early bipotential mammalian gonad into either testis or ovary. Dr. Capel’s work on signaling pathways in the gonad led to the widely accepted current model that sex determination results from antagonism between the male and female transcriptional and cell signaling networks. She pioneered organ culture techniques for studying the organogenesis of the testis and ovary, and was among the first to develop live imaging to explore the critical role of the vasculature in the morphogenesis of the gonad. Recently, she has used systems-biology and mouse genetics approaches to characterize the global transcriptional network underlying gonad fate, and has investigated the conservation of these mechanisms in the red-eared slider turtle, in which sex determination is thermally regulated. Other work in her laboratory aims to understand how the intracellular program in germ cells, in combination with regulation from their niche, leads to the transition of germ cells from a pluripotent state into pro-spermatogonia.
    [Show full text]
  • Rudolf Jaenisch
    RUDOLF JAENISCH Date of Birth: April 22, 1942 Place of Birth: Wolfelsgrund, Germany Citizenship: United States Education: M.D. 1967, University of Munich, Germany Associations, Memberships and Honors: Member, National Academy of Sciences Member, National Institute of Medicine Member, International Society for Stem Cell Research Member, American Association for the Advancement of Science Member, German Academy of Natural Sciences Leopoldina Associate Member, European Molecular Biology Organization Editorial Board, Proceedings of the National Academy of Sciences, 2004- Editorial Board, Developmental Dynamics, 1992-2000 1996 Boehringer Mannheim Molecular Bioanalytics Prize 2001 First Peter Gruber Foundation Award in Genetics 2002 Robert Koch Prize for Excellence in Scientific Achievement 2003 Charles Rodolphe Brupracher Foundation Cancer Award 2006 Max Delbrück Medal for Molecular Medicine 2007 Vilcek Foundation Prize for Achievements of Prominent Immigrants 2008 Meira and Shaul G. Massry Prize 2009 James R. Killian Jr. Faculty Achievement Award 2009 Ernst Schering Prize 2010 Orden Pour le Mérite 2010 Kazemi Prize of the Royan Institute 2010 Order of Merit of the Federal Republic of Germany 2011 MGH Warren Triennial Prize 2011 Wolf Prize for Medicine 2011 United States National Medal of Science 2011 J. Allyn Taylor International Prize in Medicine 2012 ISSCR McEwen Award for Innovation 2012-Vice President, International Society for Stem Cell Research 2013 Franklin Institute Laureate Professional Experience: 9/68-1/70 Postdoctoral Fellow, Max Planck Institute for Biochemistry, Munich; replication and transcription of E. coli phages M13 and PhiX174. 2/70-2/72 Postdoctoral Fellow with Dr. Arnold Levine, Department of Biochemistry, Princeton University; Replication, transcription, and transformation with SV40 virus. 2/72-10/72 Visiting Fellow with Dr.
    [Show full text]
  • III IIHIIII USOO5550316A United States Patent (19) 11 Patent Number: 5,550,316 Mintz 45) Date of Patent: Aug
    III IIHIIII USOO5550316A United States Patent (19) 11 Patent Number: 5,550,316 Mintz 45) Date of Patent: Aug. 27, 1996 54) TRANSGENIC ANIMAL MODEL SYSTEM M Bradlet al. (1991) Proc Natl AcadSci, USA 88:164-168. FOR HUMAN CUTANEOUS MELANOMA K N Broadley et al (1989) Laboratory Investigation 61:571-575. 75) Inventor: Beatrice Mintz, Elkins Park, Pa. Hesketh (1995) The Oncogene Facts Book, pp. 32-42. (73) Assignee: Fox Chase Cancer Center, Strojek et al (1988) Genetic Engineering: Principles and Philadelphia, Pa. methods, 10:238. Loudon et al (1993) Clin Exp Pharmacol Physiol 20: 21 Appl. No.: 11,060 283-288. 22 Filed: Jan. 29, 1993 Primary Examiner-Jacqueline M. Stone Related U.S. Application Data Assistant Examiner-Bruce R. Campell Attorney, Agent, or Firm-Pennie & Edmonds 63 Continuation-in-part of Ser. No. 636,798, Jan. 2, 1991, abandoned. 57) ABSTRACT (51 Int. CI.' ................ C12N 15/00; A01K 67/00 52) U.S. Cl. ..................... 800/2; 800/DIG. 1; 435/172.3; The present invention relates to transgenic animal model 536/23.1; 536/23.72; 536/24.1; 424/9.2 systems for human cutaneous melanoma. It is based, at least Field of Search ................................... 800/2, DIG. 1; in part, on the discovery that, in susceptible transgenic mice, (58) accelerated formation of melanoma tumors occurred near 435/172.3; 536/23.1, 23.72, 24.1; 424/9 the wound borders of skin grafts carrying the Tyr-SV40E References Cited transgene, indicating that factors present during wound (56) healing facilitate the formation of cutaneous melanoma in PUBLICATIONS susceptible tissue.
    [Show full text]
  • Normal Genetically Mosaic Mice Produced from Malignant
    Proc. Nat. Acad. Sci. USA Vol. 72, No. 9, pp. 3585-589, September 1975 Cell Biology Normal genetically mosaic mice produced from malignant teratocarcinoma cells (embryonal carcinoma/teratoma/embryoid body core cells/blastocyst injection/allophenic mice) BEATRICE MINTZ AND KARL ILLMENSEE Institute for Cancer Research, Fox Chase, Philadelphia, Pennsylvania 19111 C6ntributed by Beatrice Mintz, June 26, 1975 ABSTRACT Malignant mouse teratocarcinoma (or em- The most rigorous test possible for developmental totipo- bryonal carcinoma) cells with a normal modal chromosome tency would be significant contributions of the carcinoma number were taken from the "cores" of embryoid bodies cells to the normal differentiation of virtually all tissues in a grown only in vivo as an ascites tumor for 8 years, and were mouse. For this to occur, the initially malignant cells would injected into blastocysts bearing many genetic markers, in order to test the developmental capacities, genetic constitu- presumably have to be brought into association with early tion, and reversibility of malignancy of the core cells. Ninety- embryo cells so that the latter could provide an organiza- three live normal pre- and postnatal animals were obtained. tional framework appropriate for normal development. The Of 14 thus far analyzed, three were cellular genetic mosaics experiment is analogous to production of allophenic mice with substantial contributions of tumor-derived cells in many (6). developmentally unrelated tissues, including some never The projected teratoma studies in this laboratory involve seen in the solid tumors that form in transplant hosts. The tissues functioned normally and synthesized their specific the use of mutagenized embryonal carcinoma cells for ex- products (e.g., immunoglobulins, adult hemoglobin, liver pro- perimental analyses of genetic regulatory systems in mam- teins) coded for by strain-type alleles at known loci.
    [Show full text]
  • Karl Oskar Illmensee (1939–) [1]
    Published on The Embryo Project Encyclopedia (https://embryo.asu.edu) Karl Oskar Illmensee (1939–) [1] By: Lancaster, Cheryl Karl Oskar Illmensee studied the cloning [2] and reproduction of fruit flies, mice, and humans [3] in the US and Europe during the twentieth and twenty-first centuries. Illmensee used nuclear transfer techniques (cloning [2]) to create early mouse [4] embryos from adult mouse [4] cells, a technique biologists used in later decades to help explain how embryonic cells function during development. In the early 1980s, Illmensee faced accusations of fraud when others were unable to replicate the results of his experiments with cloned mouse [4] embryos. Illmensee also worked with human embryos, investigating how embryos split to form identical twins. Illmensee was born in Lindau, Austria, in 1939. At the Ludwig Maximilians Universität in München, Germany, he studied chemistry and biology before beginning his PhD research in the Zoologisches Institut der Universität (University Department of Zoology), part of the Ludwig Maximilians Universität. Illmensee studied the developmental genetics of fruit flies. Two other researchers, Robert Briggs and Thomas King at the American Institute for Cancer Research [5] in Washington, USA, had cloned frogs in the 1950s. Illmensee attempted to use Briggs and King's method to clone fruit fliesD (rosophila melanogaster [6]). Despite failing to clone an adult fly, Illmensee published the results of his research in 1968. Illmensee exchanged the nucleus [7] of an unfertilized fly egg [8] with a nucleus [7] from a fertilized fly egg [8], a process called nuclear transplantation. Of the 118 eggs that had undergone nuclear transplantation, 11 began to develop, and one developed into the larval stage, the stage right before adulthood in fruit flies.
    [Show full text]
  • History of The
    HISTORY OF THE AMERICAN GYNECOLOGICAL SOCIETY 1876-1981 AND AMERICAN ASSOCIATION OF OBSTETRICIANS AND GYNECOLOGISTS 1888-1981 EDWARD STEWART TAYLOR Denver, Colorado The C. V. Mosby Company ST. LOUIS, MISSOURI 1985 Copyright © 1985 by The C. V. Mosby Company All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or trans- mitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America The C. V. Mosby Company 11830 Westline Industrial Drive, St. Louis, Missouri 63146 Library of Congress Cataloging in Publication Data Taylor, E. Stewart (Edward Stewart), 1911- History of the American Gynecological Society, 1876- 1981, and the American Associate of Obstetricians and Gynecologists, 1888-1981. Includes index. 1. American Gynecological Society—History. 2. American Association of Obstetricians and Gynecologists—History. I. American Gynecological Society. II. American Association of Obstetricians and Gynecologists. III. Title. [DNLM: Gynecology—history—United States. 2. Obstetrics— history—United States. 3. Societies, Medical—history— United States, WP 1 A512T] RG1.A567T39 1985 618'.06’073 85-4768 ISBN 0-8016-5101-8 GW/OB/RR 9 8 7 6 5 4 3 2 1 01/C/088 Contents Preface. ......................................................................................................................................................... 5 Introduction. ................................................................................................................................................
    [Show full text]
  • March of Dimes Prize in Developmental Biology Recipient List
    MARCH OF DIMES PRIZE IN DEVELOPMENTAL BIOLOGY RECIPIENT LIST 2015 Investigator, Howard Hughes Medical Institute Rudolf Jaenisch, MD Whitehead Institute for Biomedical Research, For pioneering work in human cytogenetics and the normal and and Professor of Biology abnormal function and behavior of the X and Y chromosomes. Massachusetts Institute of Technology, Cambridge, MA 2010 For devising innovative technologies that elucidated long-standing Shinya Yamanaka, MD, PhD * dilemmas in developmental biology, for recognizing the L.K. Whittier Foundation Investigator in Stem Cell Biology transformative significance on cellular function of epigenetic Gladstone Institute of Cardiovascular Disease programming, and for applying the power of induced pluripotent Professor, University of California, San Francisco stem cells to novel discoveries. Director, Center for iPS Cell Research and Application 2014 For research on how certain master genes and protein signals regulate Huda Y. Zoghbi, MD formation and growth of organs such as the brain and limbs during Professor, Departments of Pediatrics; Molecular and Human Genetics; embryonic and fetal development. Neurology; Neuroscience; Programs in Cell and Molecular Biology and Developmental Biology 2009 Baylor College of Medicine, Houston, TX Kevin P. Campbell, PhD Carver Chair, Department of Molecular Physiology & Biophysics For pioneering work evolving from discovery that mutations in the X- Director of the Wellstone Muscular Dystrophy Cooperative Research linked MECP2 cause Rett syndrome and for studies elucidating the Center maintenance role of this epigenetic regulator in different neurons. Professor of Neurology and Internal Medicine 2013 University of Iowa, Roy J. and Lucille A. Carver College of Medicine, Eric Olson, PhD Iowa City, Iowa Annie and Willie Nelson Professorship in Stem Cell Research & Louis M.
    [Show full text]
  • The Origins of Oncomice: a History of the First Transgenic Mice Genetically Engineered to Develop Cancer
    Downloaded from genesdev.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press HISTORICAL PERSPECTIVE The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer Douglas Hanahan,1,4 Erwin F. Wagner,2 and Richard D. Palmiter3 1Department of Biochemistry and Biophysics, Diabetes Center, and Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA; 2Research Institute for Molecular Pathology (IMP), Vienna A-1030, Austria; 3Department of Biochemistry, University of Washington, Seattle, Washington 98195, USA This perspective describes the concurrent development cells within normal tissues of a mammalian organism in the 1980s of the first transgenic mice genetically en- could lead to tumor development. In 1992, gene knock- gineered to express dominant oncogenes, involving inde- out technology converged in a similar fashion with tu- pendent researchers who were largely unaware of each mor suppressor genetics in the generation of mice that other’s strategies and progress. We relate the experimen- developed cancers by virtue of lacking tumor suppressor tal designs, the pitfalls and challenges encountered, and gene function (for review, see Jacks 1996). the eventual success in developing distinctive mouse The significance of these early technological innova- models of cancer, wherein tumors arose heritably in vari- tions, which lead to genetically engineered mice en- ous organs. These early oncomice have produced a dowed to heritably develop particular forms of cancer, wealth of new knowledge, become topics of intellectual can be appreciated by considering the scientific/techni- property, and spawned a vibrant field of cancer research cal landscape then, and now.
    [Show full text]
  • Gail Roberta Martin (1944– ) [1]
    Published on The Embryo Project Encyclopedia (https://embryo.asu.edu) Gail Roberta Martin (1944– ) [1] By: Villarreal, Lance Keywords: Embryonic Stem Cells [2] In the twentieth and early twenty-first centuries, Gail Roberta Martin specialized in biochemistry ande mbryology [3], more specifically cellular communication and the development of organs. In 1981, she named any cell taken from inside a human embryo at the blastocyst [4] stage an “embryonic stem cell”. During development, an embryo goes through theb lastocyst [4] stage just before it implants in the uterus [5]. Embryonic stem cells [6] are useful for experiments because they are self-renewing and able to develop into almost any cell type in the body. Martin later identified a key chemical component in limb development and continues to study embryogenesis [7], or the growth of embryos over time. Martin’s work one mbryonic stem cells [8] has allowed scientists to further research and treat human diseases, and her study of how organs form has helped scientists learn about the healthy growth of embryos. Martin was born in New York City, New York on 2 April 1944. She received her Bachelor of Arts degree in zoology from the University of Wisconsin, Madison in Madison, Wisconsin, in 1964. In the late 1960s, Martin studied as a graduate student at the University of California at Berkeley [9] in Berkeley, California, and worked under Harry Rubin studying how the Rous sarcoma [10] virus affected chicken [11] cells’ genetic material, commonly known as DNA, or deoxyribonucleic acid. When injected in to chickens, the Rous sarcoma [10] virus causes tumors to develop.
    [Show full text]